FTO and cancer: Rui Su et al. demonstrated that genetic depletion of FTO Alpha-Ketoglutarate Dependent Dioxygenase (FTO) and drug inhibition largely attenuated the self-renewal of leukemic stem cells and inhibited the gene expression of immune checkpoint genes, and reprogrammed the immune response; thus, making cancer therapy targeting FTO a potential therapeutic modality6.